The Young Investigator Award (YIA) provides funding to promising investigators to encourage and promote quality research in clinical oncology. The purpose of this research grant is to fund physicians during the transition from a fellowship program to a faculty appointment.
The Young Investigator Award (YIA) is a one-year research grant totaling $50,000, paid in two increments to the awardee’s institution. The applicant must be a physician (MD, DO, or international equivalent) who is currently within the last two years of his/her final subspecialty training at an academic medical institution at the time of grant submission. Applicants should be planning an investigative career in clinical oncology.
For more information on the YIA, please read the most recent Request for Proposals.
The 2012 YIAs are supported by:
| Abbott Laboratories | Lilly USA, LLC |
| Amgen | Merck Oncology |
| Astellas Pharma US Inc. | Millennium: The Takeda Oncology Company (2) |
| The Breast Cancer Research Foundation (2) | Novartis Pharmaceuticals (2) |
| Bristol-Myers Squibb | Onyx Pharmaceuticals Inc. |
| Celgene Corporation | Pfizer |
| Daiichi Sankyo, Inc. | Roche Pharmaceuticals (5) |
| The Don Shula Foundation | Sarcoma Foundation of America |
| Eisai Inc. (2) | Seattle Genetics |
| Genentech BioOncology™ (5) | The Strike 3 Foundation |
| Kidney Cancer Association | Teva Pharmaceuticals |
The WWWW Foundation, Inc. (QuadW) and The Sarcoma Fund of the QuadW Foundation |